ENANTA PHARMACEUTICALS INC (ENTA)
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
📈 **POSITIVE** • Medium confidence analysis (80%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business